Frank Dicker
YOU?
Author Swipe
View article: Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study.
Primary asciminib resistance in a chronic myeloid leukemia patient with the atypical BCR::ABL1 e13a3 transcript: a case study. Open
Not available.
View article: Effect of Whole Bowel Irrigation for Ingested Lead-Containing Foreign Bodies: A Pediatric Case Series
Effect of Whole Bowel Irrigation for Ingested Lead-Containing Foreign Bodies: A Pediatric Case Series Open
Background Foreign body (FB) ingestions cause lead toxicity in pediatric patients. These ingestions result in continued lead absorption until passage or removal from the gastrointestinal (GI) tract. Whole-bowel irrigation (WBI) is frequent…
View article: Proximally biased V(D)J recombination in the clonal evolution of IGH alleles in <i>KMT2A::AFF1</i> BCP‐ALL of all age classes
Proximally biased V(D)J recombination in the clonal evolution of IGH alleles in <i>KMT2A::AFF1</i> BCP‐ALL of all age classes Open
We report the analysis of 379 cases of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) using whole-transcriptome sequencing data (Table S1 and Supporting Information S1: Methods). In 48 adult, 36 pediatric, and 37 infant cases of B…
View article: Modification of the ELN Classification 2022 Refines Risk Assessment in MDS/AML Patients
Modification of the ELN Classification 2022 Refines Risk Assessment in MDS/AML Patients Open
Background: The International Consensus Classification (ICC) introduced MDS/AML as a novel myeloid disease entity defined by 10-19% blasts in the absence of AML-defining recurrent genetic abnormalities. MDS/AML patients should be eligible …
View article: P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED? Open
Background: MDS/AML has recently been introduced as novel myeloid disease entity by the International Consensus Classification (ICC) with 10–19% blasts in the absence of AML-defining recurrent genetic abnormalities. MDS/AML is not recogniz…
View article: AML classification in the year 2023: How to avoid a Babylonian confusion of languages
AML classification in the year 2023: How to avoid a Babylonian confusion of languages Open
In parallel to the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO 2022), an alternative International Consensus Classification (ICC) has been proposed. To evaluate the impact of the new classifi…
View article: Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration Open
In AML patients, recurrent mutations were shown to persist in remission, however, only some have a prognostic value and persistent mutations might therefore reflect a re-established premalignant state or truly active disease causing relaps…
View article: NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse
NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse Open
Acute myeloid leukemia (AML) with NPM1 mutation (NPM1mut) defines a World Health Organization entity. Absence of minimal residual disease (MRD) following induction chemotherapy is associated with an excellent prognosis. Data are conflictin…